Aspirin Does Not Increase Heart Failure Events in Heart Failure Patients : From the WARCEF Trial
Copyright © 2017 American College of Cardiology Foundation. All rights reserved..
OBJECTIVES: The aim of this study was to determine whether aspirin increases heart failure (HF) hospitalization or death in patients with HF with reduced ejection fraction receiving an angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB).
BACKGROUND: Because of its cyclooxygenase inhibiting properties, aspirin has been postulated to increase HF events in patients treated with ACE inhibitors or ARBs. However, no large randomized trial has addressed the clinical relevance of this issue.
METHODS: We compared aspirin and warfarin for HF events (hospitalization, death, or both) in the 2,305 patients enrolled in the WARCEF (Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction) trial (98.6% on ACE inhibitor or ARB treatment), using conventional Cox models for time to first event (489 events). In addition, to examine multiple HF hospitalizations, we used 2 extended Cox models, a conditional model and a total time marginal model, in time to recurrent event analyses (1,078 events).
RESULTS: After adjustment for baseline covariates, aspirin- and warfarin-treated patients did not differ in time to first HF event (adjusted hazard ratio: 0.87; 95% confidence interval: 0.72 to 1.04; p = 0.117) or first hospitalization alone (adjusted hazard ratio: 0.88; 95% confidence interval: 0.73 to 1.06; p = 0.168). The extended Cox models also found no significant differences in all HF events or in HF hospitalizations alone after adjustment for covariates.
CONCLUSIONS: Among patients with HF with reduced ejection fraction in the WARCEF trial, there was no significant difference in risk of HF events between the aspirin and warfarin-treated patients. (Warfarin Versus Aspirin in Reduced Cardiac Ejection Fraction trial [WARCEF]; NCT00041938).
| Errataetall: |
CommentIn: JACC Heart Fail. 2017 Aug;5(8):611-614. - PMID 28774397 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2017 |
|---|---|
| Erschienen: |
2017 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:5 |
|---|---|
| Enthalten in: |
JACC. Heart failure - 5(2017), 8 vom: 08. Aug., Seite 603-610 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Teerlink, John R [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 07.05.2018 Date Revised 06.03.2020 published: Print ClinicalTrials.gov: NCT00041938 CommentIn: JACC Heart Fail. 2017 Aug;5(8):611-614. - PMID 28774397 Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.jchf.2017.04.011 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM274484064 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM274484064 | ||
| 003 | DE-627 | ||
| 005 | 20231225003601.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jchf.2017.04.011 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0914.xml |
| 035 | |a (DE-627)NLM274484064 | ||
| 035 | |a (NLM)28774396 | ||
| 035 | |a (PII)S2213-1779(17)30281-0 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Teerlink, John R |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Aspirin Does Not Increase Heart Failure Events in Heart Failure Patients |b From the WARCEF Trial |
| 264 | 1 | |c 2017 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 07.05.2018 | ||
| 500 | |a Date Revised 06.03.2020 | ||
| 500 | |a published: Print | ||
| 500 | |a ClinicalTrials.gov: NCT00041938 | ||
| 500 | |a CommentIn: JACC Heart Fail. 2017 Aug;5(8):611-614. - PMID 28774397 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2017 American College of Cardiology Foundation. All rights reserved. | ||
| 520 | |a OBJECTIVES: The aim of this study was to determine whether aspirin increases heart failure (HF) hospitalization or death in patients with HF with reduced ejection fraction receiving an angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) | ||
| 520 | |a BACKGROUND: Because of its cyclooxygenase inhibiting properties, aspirin has been postulated to increase HF events in patients treated with ACE inhibitors or ARBs. However, no large randomized trial has addressed the clinical relevance of this issue | ||
| 520 | |a METHODS: We compared aspirin and warfarin for HF events (hospitalization, death, or both) in the 2,305 patients enrolled in the WARCEF (Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction) trial (98.6% on ACE inhibitor or ARB treatment), using conventional Cox models for time to first event (489 events). In addition, to examine multiple HF hospitalizations, we used 2 extended Cox models, a conditional model and a total time marginal model, in time to recurrent event analyses (1,078 events) | ||
| 520 | |a RESULTS: After adjustment for baseline covariates, aspirin- and warfarin-treated patients did not differ in time to first HF event (adjusted hazard ratio: 0.87; 95% confidence interval: 0.72 to 1.04; p = 0.117) or first hospitalization alone (adjusted hazard ratio: 0.88; 95% confidence interval: 0.73 to 1.06; p = 0.168). The extended Cox models also found no significant differences in all HF events or in HF hospitalizations alone after adjustment for covariates | ||
| 520 | |a CONCLUSIONS: Among patients with HF with reduced ejection fraction in the WARCEF trial, there was no significant difference in risk of HF events between the aspirin and warfarin-treated patients. (Warfarin Versus Aspirin in Reduced Cardiac Ejection Fraction trial [WARCEF]; NCT00041938) | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a aspirin | |
| 650 | 4 | |a heart failure | |
| 650 | 4 | |a hospitalization | |
| 650 | 4 | |a survival | |
| 650 | 4 | |a warfarin | |
| 650 | 7 | |a Angiotensin Receptor Antagonists |2 NLM | |
| 650 | 7 | |a Angiotensin-Converting Enzyme Inhibitors |2 NLM | |
| 650 | 7 | |a Anticoagulants |2 NLM | |
| 650 | 7 | |a Cyclooxygenase Inhibitors |2 NLM | |
| 650 | 7 | |a Warfarin |2 NLM | |
| 650 | 7 | |a 5Q7ZVV76EI |2 NLM | |
| 650 | 7 | |a Aspirin |2 NLM | |
| 650 | 7 | |a R16CO5Y76E |2 NLM | |
| 700 | 1 | |a Qian, Min |e verfasserin |4 aut | |
| 700 | 1 | |a Bello, Natalie A |e verfasserin |4 aut | |
| 700 | 1 | |a Freudenberger, Ronald S |e verfasserin |4 aut | |
| 700 | 1 | |a Levin, Bruce |e verfasserin |4 aut | |
| 700 | 1 | |a Di Tullio, Marco R |e verfasserin |4 aut | |
| 700 | 1 | |a Graham, Susan |e verfasserin |4 aut | |
| 700 | 1 | |a Mann, Douglas L |e verfasserin |4 aut | |
| 700 | 1 | |a Sacco, Ralph L |e verfasserin |4 aut | |
| 700 | 1 | |a Mohr, J P |e verfasserin |4 aut | |
| 700 | 1 | |a Lip, Gregory Y H |e verfasserin |4 aut | |
| 700 | 1 | |a Labovitz, Arthur J |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Seitetz C |e verfasserin |4 aut | |
| 700 | 1 | |a Ponikowski, Piotr |e verfasserin |4 aut | |
| 700 | 1 | |a Lok, Dirk J |e verfasserin |4 aut | |
| 700 | 1 | |a Anker, Stefan D |e verfasserin |4 aut | |
| 700 | 1 | |a Thompson, John L P |e verfasserin |4 aut | |
| 700 | 1 | |a Homma, Shunichi |e verfasserin |4 aut | |
| 700 | 0 | |a WARCEF Investigators |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t JACC. Heart failure |d 2013 |g 5(2017), 8 vom: 08. Aug., Seite 603-610 |w (DE-627)NLM22747550X |x 2213-1787 |7 nnns |
| 773 | 1 | 8 | |g volume:5 |g year:2017 |g number:8 |g day:08 |g month:08 |g pages:603-610 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jchf.2017.04.011 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 5 |j 2017 |e 8 |b 08 |c 08 |h 603-610 | ||